HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.8%

Neg 0% Neu 90.8% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $42 price target.